Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL2889770 | 0.83 | MAPT (0.60) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL17132355 | 0.82 | MAPT (0.59) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL22048165 | 0.82 | MAPT (0.58) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL1697621 | 0.82 | MAPT (0.67) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL2890893 | 0.81 | MAPT (0.51) | MAPTKMT2AMAPK1MEN1RECQL | |
| SCHEMBL26686689 | 0.79 | MAPT (0.66) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL16273773 | 0.78 | MAPT (0.54) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL1339942 | 0.77 | ALDH1A1 (0.57) | MAPTKMT2AMAPK1MEN1L3MBTL1 | |
| SCHEMBL14874247 | 0.77 | MAPT (0.62) | MAPTRECQLAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL14401083 | 0.76 | MAPT (0.52) | MAPTKMT2AMAPK1MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286197-A1 | Carboxamide Derivatives As Therapeutic Agents | TRANSTECH PHARMA, INC. | 2010-11-11 | — | — | US | disclosed |
| US-7776919-B2 | Carboxamide derivatives as therapeutic agents | TransTech Pharm, Inc. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7423177-B2 | Carboxamide derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080119512-A1 | Carboxamide Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1377295-A4 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1377295-A2 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20020193432-A1 | Carboxamide derivatives as therapeutic agents | VTVX HOLDINGS I LLC | 2002-12-19 | — | — | US | disclosed |
| WO-2002070473-A2 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286197-A1 | Carboxamide Derivatives As Therapeutic Agents | AGER, S100B, S100A4 | MAPT 655/4885KMT2A 4158/4885MAPK1 2058/4885 |
| US-20020193432-A1 | Carboxamide derivatives as therapeutic agents | AGER, S100B, S100A4 | MAPT 624/4885KMT2A 4120/4885MAPK1 2061/4885 |
| US-20080119512-A1 | Carboxamide Derivatives as Therapeutic Agents | AGER, S100B, S100A4 | MAPT 655/4885KMT2A 4158/4885MAPK1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.